Results 171 to 180 of about 50,045 (313)
Immunogenicity assessment of concizumab in patients with Hemophilia A and b: Assays developed to measure anti-drug antibodies and integrated results from clinical trials [PDF]
Luis Perez Tosar +2 more
openalex +1 more source
Abstract Purpose Patello–femoral instability (PFI) is often caused by predisposing factors, with trochlea dysplasia (TD) as the most prominent. Untreated patellar instability leads to impaired function and an increased risk of patellofemoral osteoarthritis.
Christian Dippmann +4 more
wiley +1 more source
Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural study. [PDF]
Astermark J +6 more
europepmc +1 more source
ABSTRACT Background Hemophilia A (HA) is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. Prophylactic FVIII replacement therapy is essential for preventing bleeds, but it carries a risk of inhibitor development, especially in previously untreated and minimally treated patients (PUPs and MTPs, respectively).
Sarina Levy‐Mendelovich +11 more
wiley +1 more source
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B. [PDF]
Reiss UM +27 more
europepmc +1 more source
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system [PDF]
Frank DeRosa +10 more
openalex +1 more source
Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting [PDF]
Cihan Ay +4 more
openalex +1 more source
Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components
The review presents a comprehensive overview of each component of lipid nanoparticles(LNPs)and their effects on editing efficiency. It specifically highlights strategies for achieving non‐liver delivery, aiming for broader applications in gene editing. Furthermore, this review summarizes the applications of LNPs in gene editing and offers insights for ...
Fan Wu +6 more
wiley +1 more source
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. [PDF]
Xue F +18 more
europepmc +1 more source

